Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Frontiers in Pediatrics Année : 2020

Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports

1 Hôpital Necker - Enfants Malades [AP-HP]
2 Service de neurologie pédiatrique [CHU Necker]
3 Clinical Research Department, Necker–Enfants Malades Hospital, APHP, Paris, France
4 Physical Rehabilitation Department, Necker–Enfants Malades Hospital, APHP, Paris , France
5 Physical Rehabilitation Department, Necker–Enfants Malades Hospital, APHP, Paris , France
6 Service de Pédiatrie Néonatale et Réanimation – Neuropédiatrie [CHU Rouen]
7 Maladies Neuromusculaires de l'Enfant
8 AMU MED - Aix-Marseille Université - Faculté de médecine
9 Pôle Enfants [CHU Toulouse]
10 Biostatistiques santé
11 Service de neuropédiatrie
12 CHU Trousseau [APHP]
13 American Memorial Hospital (Reims)
14 CHU BREST Pédiatrie - CHRU de Brest - Département de Pédiatrie
15 Hôpital de Hautepierre [Strasbourg]
16 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
17 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
18 Pediatric Neurology Department, University Hospital, Ang ers, France,
19 Service de pédiatrie
20 IP - Institut Pascal
21 CHU La Réunion - Centre Hospitalier Universitaire de La Réunion
22 Centre de génétique - Centre de référence des maladies rares, anomalies du développement et syndromes malformatifs (CHU de Dijon)
23 Palliative Care Team, Necker–Enfants Malades Hospital, AP HP, Paris, France
24 ETRES - Éthique, recherches, translations = Ethics, research, translations [CRC]
25 Service de neurométabolisme
26 Pediatric Neurology Department, Necker–Enfants Malades H ospital, APHP, Paris, France
Carole Vuillerot
Caroline Espil
  • Fonction : Auteur
  • PersonId : 889695
Catherine Sarret

Résumé

Spinal muscular atrophy type 1 (SMA-1) is a severe neurodegenerative disorder, which in the absence of curative treatment, leads to death before 1 year of age in most cases. Caring for these short-lived and severely impaired infants requires palliative management. New drugs (nusinersen) have recently been developed that may modify SMA-1 natural history and thus raise ethical concerns about the appropriate level of care for patients. The national Hospital Clinical Research Program (PHRC) called "Assessment of clinical practices of palliative care in children with Spinal Muscular Atrophy Type 1 (SMA-1)" was a multicenter prospective study conducted in France between 2012 and 2016 to report palliative practices in SMA-1 in real life through prospective caregivers' reports about their infants' management. Thirty-nine patients were included in the prospective PHRC (17 centers). We also studied retrospective data regarding management of 43 other SMA-1 patients (18 centers) over the same period, including seven treated with nusinersen, in comparison with historical data from 222 patients previously published over two periods of 10 years (1989-2009). In the latest period studied, median age at diagnosis was 3 months [0.6-10.4]. Seventy-seven patients died at a median 6 months of age[1-27]: 32% at home and 8% in an intensive care unit. Eighty-five percent of patients received enteral nutrition, some through a gastrostomy (6%). Sixteen percent had a non-invasive ventilation (NIV). Seventy-seven percent received sedative treatment at the time of death. Over time, palliative management occurred more frequently at home with increased levels of technical supportive care (enteral nutrition, oxygenotherapy, and analgesic and sedative treatments). No statistical difference was found between the prospective and retrospective patients for the last period. However, significant differences were found between patients treated with nusinersen vs. those untreated. Our data confirm that palliative care is essential in management of SMA-1 patients and that parents are extensively involved in everyday patient care. Our data suggest that nusinersen treatment was accompanied by significantly more invasive supportive care, indicating that a re-examination of standard clinical practices should explicitly consider what treatment pathways are in infants' and caregivers' best interest. This study was registered on clinicaltrials.gov under the reference NCT01862042 (https://clinicaltrials.gov/ct2/show/study/NCT01862042?cond=SMA1&rank=8).
Fichier principal
Vignette du fichier
2020 Hully et al., Palliative.pdf (43.36 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02500990 , version 1 (07-07-2020)

Identifiants

Citer

Marie Hully, Christine Barnérias, Delphine Chabalier, Sophie Le Guen, Virginie Germa, et al.. Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports. Frontiers in Pediatrics, 2020, 8, pp.4. ⟨10.3389/fped.2020.00004⟩. ⟨hal-02500990⟩
180 Consultations
25 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More